Join Now

Author Archives: Denise Bell

Rep. Burgess Owens Spends a Day in the BioHive

Utah life sciences companies took center stage September 2, as U.S. Representative Burgess Owens (R-UT) toured Canyon Labs, Ultradent (Canyon Labs’ parent company), Ortho Development and Xenter – all innovative leaders in advancing medical technologies that improve patient care and provide jobs for hundreds of Utahns. BioUtah helped to facilitate the BioHive day. “Utah is […]

Posted in BioUtah News, Industry News, Life Sciences Industry News | Leave a comment

Senator Mike Lee Spends a Day in the BioHive

U.S. Senator Mike Lee (R-UT) on August 15 spent the day connecting with Utah’s life sciences community, known as the BioHive, touring facilities at BD, IONIQ Sciences, SEEK Labs and Carterra. His schedule also included a tour of Altitude Lab in the University of Utah’s Research Park where he led a roundtable discussion with nearly […]

Posted in Policy News | Leave a comment

Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-5336, an Investigational Menin and Mixed-Lineage Leukemia Binding Protein for Treatment of Acute Myeloid Leukemia 

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-5336, an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein, for the treatment of acute myeloid leukemia (AML).  “We are pleased to have […]

Posted in BioUtah News | Leave a comment

Senate Democrats Push Drug Pricing, Tax, Climate Package

Sen. Joe Manchin (D-W. Va.) on Wednesday said he had signed off on a revised “Build Back Better” plan, renamed the “Inflation Reduction Act of 2022,” which includes sweeping drug price controls along with tax increases and billions for climate and energy spending. The bill’s drug pricing provisions would allow Medicare to negotiate drug prices […]

Posted in Policy News | Leave a comment

BioUtah Joins State BIOs in Opposing Drug Price Controls

Senate Democrats are inching closer to a vote on a revived “Build Back Better” package, largely focused on drug pricing. The package would give Medicare the authority to negotiate drug prices and impose inflation rebates. The negotiation process, in practice, would function more like government price controls since drug manufacturers deemed non-compliant with the requirements […]

Posted in Policy News | Leave a comment

Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, recently announced that the FDA granted Orphan Drug Designation for TP-3654, the company’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.  “This designation is an important milestone in the development of TP-3654 and highlights the need for potential new treatment […]

Posted in Policy News | Leave a comment

Sumitomo Pharma Oncology, Inc. Pursues Research and Discovery with Persistence – Featured in Pharma Tech Outlook

Sumitomo Pharma Oncology, Inc. (SMP Oncology) and Steve Warner, Ph.D., Senior Vice President and Head of US Research at SMP Oncology, were recently featured in a Pharma Tech Outlook. In “Sumitomo Pharma Oncology: Discovering Immunotherapy Agents with Persistence,” Dr. Warner discusses SMP Oncology’s ongoing work in immunotherapy drug discovery, highlighting the progress with the Company’s […]

Posted in Policy News | Leave a comment

Invest Lithuania

BioUtah has established a partnership with Invest Lithuania, an arm of the Lithuanian government focused on developing life sciences in their country. The life sciences sector in Lithuania is regarded as one of the most highly developed in Central and Eastern Europe (CEE). The sector is driven by innovation and aims to become Europe’s next […]

Posted in Policy News | Leave a comment

BioHive Takes the Stage at One Utah Summit

The BioHive community was featured prominently at the One Utah Summit held on May 10 at the Grand America Hotel in Salt Lake City. Speakers from the life sciences industry addressed the crowd on topics ranging from job creation and talent development to life-saving innovation and drug discovery. Tom Polen, CEO of BD, and Rob […]

Posted in BioUtah News, Industry News, Life Sciences Industry News, Utah's Life Sciences Companies | Leave a comment

Recursion Co-Founder and CEO, Chris Gibson, Awarded Governor’s Medal for Science and Technology

Recursion Co-founder and CEO, Chris Gibson, Ph.D., was honored at the One Utah Summit on May 10, receiving the Governor’s Medal for Science and Technology. Gov. Spencer Cox presented the award during the summit’s special recognition ceremony. The prestigious award commends the distinguished service, significant achievement, and positive economic impact of individuals to the state […]

Posted in BioUtah News, Industry News, Life Sciences Industry News, Utah's Life Sciences Companies | Leave a comment

Healthcare Priorities of President Biden’s FY23 Budget

On Monday, March 28, President Biden announced his budget for FY23, a $5.8 trillion proposal that reflects the administration’s funding priorities, many of which were drawn from the initial Build Back Better package.  Congress is not required to adopt any or all of the president’s budget. However, each year, the president’s budget proposal serves as […]

Posted in Policy News | Leave a comment

MDUFA V Agreement Reached

The FDA and representatives from the medical device industry have reached an agreement on proposed recommendations for MDUFA V. On March 22, FDA sent the commitment letter to Congress. Under the new agreement, the FDA would be authorized to collect at least $1.78 billion in user fees over five years. FDA could receive additional funding […]

Posted in Policy News | Leave a comment